Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibody therapeutics in oncology. The company went public through a business combination with Brookline Capital Acquisition Corp., a SPAC sponsored by Brookline Capital Markets, with the merger closing in 2022 following the blank-check vehicle's 2021 IPO. The S-1/A amendment filed September 1, 2022 represents a post-merger registration statement update with the SEC. Apexigen's pipeline centers on cancer immunotherapy, with its lead asset, sotigalimab (APX005M), a CD40 agonist antibody being evaluated in oncology indications. Visit SpacDesk and sign up for full data, filings history, and deal analytics on Apexigen and hundreds of other de-SPAC companies.